DSIP

Overview

DSIP is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) isolated in 1977 from the cerebral blood of rabbits during electrically induced sleep. Mechanism remains uncertain and the clinical evidence base is weak. Not FDA-approved — research use only.

Mechanism of Action

Mechanism is genuinely uncertain after decades of study. No specific DSIP receptor has been identified. Reported effects include modulation of CRH/cortisol signaling and interactions with GABAergic and monoaminergic systems, but these findings are inconsistent. Contemporary reviews describe DSIP as a 'still unresolved riddle.'

Research Summary

Small clinical studies, mostly from the 1980s-1990s and conducted in Europe (including Russia and Germany), explored DSIP in chronic insomnia, chronic pain, alcohol/opioid withdrawal, narcolepsy, and depression. The Schneider-Helmert trials (≤18 subjects) reported modest sleep normalization. No Phase 3 trials, no FDA approval, and no modern replication. Evidence is historical and weak.

Dosing Information

Reported Side Effects

• Generally well-tolerated in small trials
• Injection-site reactions
• Vivid dreams (reported)
• Mild GI upset (reported)
• Mild headache

Labs to monitor before & during your DSIP protocol

These biomarkers are commonly tracked to assess response and safety. Run baseline labs before starting, mid-cycle labs halfway through, and post-cycle labs 1–2 weeks after the final dose.

Commonly Stacked With

Research References

• Schoenenberger GA, Monnier M. Characterization of a delta-EEG (-sleep)-inducing peptide. PNAS. 1977;74(3):1282-6. (PMID 265572)
• Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. 1984;8(1):83-93. (PMID 6145137)
• Schneider-Helmert D. Efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacs. Eur Neurol. 1986;25(6):448-53. (PMID 3792404)
• Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006;97(2):303-9. (PMID 16539679)